Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
Diane ItoChaoling FengChristine FuChong KimJames WuJosh EpsteinJulia Thornton SniderAdam S DuVallPublished in: Expert review of pharmacoeconomics & outcomes research (2023)
During the period ending in 2020, patients relapsed frequently, incurring high HRU and costs across LoTs. More effective treatments with long-lasting remissions in R/R MCL may reduce healthcare burden.
Keyphrases
- healthcare
- acute lymphoblastic leukemia
- acute myeloid leukemia
- end stage renal disease
- diffuse large b cell lymphoma
- ejection fraction
- hodgkin lymphoma
- multiple myeloma
- public health
- chronic kidney disease
- newly diagnosed
- mental health
- health information
- palliative care
- peritoneal dialysis
- chronic pain
- social media
- pain management
- affordable care act